Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 16, 2017 - Issue 4
Submit an article Journal homepage
568
Views
4
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer

Viola ZhuChao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology, University of California, Irvine School of Medicine, Orange, California, USA;VA Long Beach Healthcare System, Hematology/Oncology Section, Long Beach, California, USACorrespondence[email protected]
View further author information
&
SH OuChao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology, University of California, Irvine School of Medicine, Orange, California, USAView further author information
Pages 509-514 | Received 09 Jan 2017, Accepted 22 Feb 2017, Published online: 03 Mar 2017

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yourong Zhou, Yiming Yin, Jiangxin Xu, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan & Xiaochun Yang. (2023) An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer. Expert Opinion on Pharmacotherapy 24:12, pages 1361-1373.
Read now
Ben W.R. Balzer, Christine Loo, Eva A. Wegner, Christa E. Nath, Samiuela Lee, Chantelle Smith, Craig R. Lewis, Toby N. Trahair & Antoinette C. Anazodo. (2018) Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung. Pediatric Hematology and Oncology 35:7-8, pages 415-421.
Read now

Articles from other publishers (2)

Jakub Hofman, Ales Sorf, Dimitrios Vagiannis, Simona Sucha, Eva Novotna, Sarah Kammerer, Jan-Heiner Küpper, Martina Ceckova & Frantisek Staud. (2019) Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metabolism and Disposition 47:7, pages 699-709.
Crossref
Tiziana Vavalà & Silvia Novello. (2018) Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology 10, pages 175883591878936.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.